Tenax Therapeutics(TENX)
$1.48-0.14 (-8.64%)
TENX
Tenax Therapeutics financials statements
$1.48
At close:-0.14 (-8.64%)
Want to see TENX full AI Analyst Report?
Tenax Therapeutics (TENX) Ratios
740 Followers
Tenax Therapeutics Ratios
TENX's free cash flow for Q3 2026 was $-12.48M. For the 2026 fiscal year, TENX's free cash flow was increased by $0.00 and operating cash flow was $-12.48M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 |
| Quick Ratio | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 |
| Cash Ratio | 13.63 | 20.21 | 2.73 | 1.15 | 3.57 |
| Solvency Ratio | -7.35 | -3.75 | -2.15 | -5.72 | -18.52 |
| Operating Cash Flow Ratio | -5.00 | -3.16 | -1.65 | -6.50 | -6.94 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -11.79 | -19.24 | 0.00 |
| Net Current Asset Value | $ 97.07M | $ 91.99M | $ 8.10M | $ 1.30M | $ 3.94M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.04 | 0.24 | 0.05 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.06 | 0.54 | 0.07 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.06 | 0.35 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.05 | 1.44 | 2.28 | 1.41 |
| Debt Service Coverage Ratio | 0.00 | -764.30 | -14.63 | -17.38 | -34103.72 |
| Interest Coverage Ratio | 0.00 | -847.57 | -343.56 | -2487.65 | -34487.08 |
| Debt to Market Cap | 0.00 | 0.00 | 0.09 | 0.19 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 2.12 | 44.17 | 22.69 |
| Net Debt to EBITDA | 1.85 | 5.40 | 1.21 | 0.12 | 0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.29% | 90.29% | 93.65% | 99.96% | 99.22% |
| Return on Assets (ROA) | -50.47% | -18.21% | -65.99% | -324.49% | -541.94% |
| Return on Equity (ROE) | -54.19% | -19.13% | -95.22% | -740.11% | -765.06% |
| Return on Capital Employed (ROCE) | -58.09% | -21.19% | -101.68% | -709.90% | -739.08% |
| Return on Invested Capital (ROIC) | -58.09% | -21.19% | -95.76% | -480.42% | -721.61% |
| Return on Tangible Assets | -50.47% | -18.21% | -65.99% | -324.49% | -541.94% |
| Earnings Yield | -11.00% | -18.62% | -141.52% | -338.24% | -151.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.91 | -0.97 | -23.81 | -653.19 | -844.18 |
| Free Cash Flow Per Share | -0.91 | -0.97 | -23.81 | -653.32 | -844.59 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -5162.39 | -2067.06 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -5162.39 | -2067.06 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -11.79 | -14.87 | -37.33 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.49% | -15.67% | -108.36% | -367.86% | -50.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.10 | -5.38 | -0.71 | -0.30 | -0.66 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.92 | 1.03 | 0.67 | 2.19 | 5.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.35 | -6.38 | -0.92 | -0.27 | -1.97 |
| Price-to-Operating Cash Flow Ratio | -13.35 | -6.38 | -0.92 | -0.27 | -1.97 |
| Price-to-Earnings Growth (PEG) Ratio | -0.55 | 0.06 | 0.01 | 0.00 | -0.04 |
| Enterprise Value Multiple | -7.23 | 0.02 | 0.50 | -0.18 | -0.50 |
| Enterprise Value | 380.49M | -319.15K | -3.84M | 1.95M | 16.11M |
| EV to EBITDA | -7.23 | 0.02 | 0.50 | -0.18 | -0.50 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -10.63 | 0.02 | 0.65 | -0.16 | -1.48 |
| EV to Operating Cash Flow | -10.63 | 0.02 | 0.65 | -0.16 | -1.48 |
| Tangible Book Value Per Share | 2.48 | 6.02 | 32.65 | 81.17 | 330.07 |
| Shareholders’ Equity Per Share | 2.48 | 6.02 | 32.65 | 81.17 | 330.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.34 | -1.15 | -31.09 | -600.72 | -2525.22 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.68 | 0.84 | 0.77 | 1.09 | 0.33 |
Currency in USD

